ITRM Iterum Therapeutics plc Stock Quote

ITRM [NASD]

Index	-	P/E	-	EPS (ttm)	-2.73	Insider Own	0.30%	Shs Outstand	176.48M	Perf Week	-10.48%
Market Cap	192.40M	Forward P/E	-	EPS next Y	-0.36	Insider Trans	-97.56%	Shs Float	175.81M	Perf Month	-28.85%
Income	-52.00M	PEG	-	EPS next Q	-0.07	Inst Own	9.00%	Short Float	2.58%	Perf Quarter	-25.50%
Sales	-	P/S	-	EPS this Y	69.50%	Inst Trans	-12.81%	Short Ratio	0.19	Perf Half Y	141.25%
Book/sh	-1.13	P/B	-	EPS next Y	-5.90%	ROA	-156.30%	Target Price	-	Perf Year	-69.34%
Cash/sh	0.10	P/C	11.38	EPS next 5Y	-	ROE	105.60%	52W Range	0.45 - 6.02	Perf YTD	12.23%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-81.56%	Beta	-
Dividend %	-	Quick Ratio	0.50	Sales past 5Y	-	Gross Margin	-	52W Low	146.12%	ATR	0.12
Employees	7	Current Ratio	0.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	40.42	Volatility	8.07% 10.06%
Optionable	No	Debt/Eq	-	EPS Q/Q	84.30%	Profit Margin	-	Rel Volume	0.30	Prev Close	1.18
Shortable	Yes	LT Debt/Eq	-	Earnings	Mar 12 BMO	Payout	-	Avg Volume	24.35M	Price	1.11
Recom	3.00	SMA20	-8.87%	SMA50	-22.02%	SMA200	1.44%	Volume	7,256,769	Change	-5.93%

Mar-15-21

Upgrade

H.C. Wainwright

Neutral → Buy

$2.50

Jun-02-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$7 → $2

Jan-21-20

Downgrade

Gabelli & Co

Buy → Sell

Dec-11-19

Downgrade

SVB Leerink

Outperform → Mkt Perform

Jun-21-19

Initiated

H.C. Wainwright

Buy

$17

Apr-06-21 08:30AM	Iterum Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire +9.09%
Mar-16-21 07:30AM	Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors GlobeNewswire +9.32%
Mar-12-21 07:00AM	Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
Mar-05-21 05:30PM	Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021 GlobeNewswire +11.03%
Feb-19-21 05:30PM	Iterum Therapeutics to Present in Upcoming Investor Conferences GlobeNewswire
Feb-17-21 10:04AM	UTILITY Therapeutics Joins Antimicrobials Working Group PR Newswire
Feb-10-21 06:40PM	Iterum Therapeutics plc Announces Exercise of Underwriters Option to Purchase Additional Ordinary Shares GlobeNewswire +20.26%
06:13AM	Iterum Therapeutics Presses Capital Raise Button To Support Potential Sulopenem Launch Activities Benzinga
Feb-09-21 11:58PM	Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules GlobeNewswire +47.40%
Feb-04-21 02:43AM	What Kind Of Investors Own Most Of Iterum Therapeutics plc (NASDAQ:ITRM)? Simply Wall St. -16.11%
Feb-03-21 11:35PM	Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million GlobeNewswire
05:51PM	Iterum Therapeutics plc Announces $10 Million Bought Deal Public Offering of Ordinary Shares GlobeNewswire
Feb-01-21 07:00AM	Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch GlobeNewswire +9.93%
Jan-25-21 07:00AM	Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem GlobeNewswire
Jan-06-21 05:00PM	Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference GlobeNewswire
Dec-23-20 07:00AM	Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors GlobeNewswire
Dec-21-20 05:00PM	Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital Market GlobeNewswire +9.16%
Dec-07-20 08:00AM	Iterum Therapeutics Announces Filing of US Patent Application Based on Favorable Written Opinion of the International Search Authority GlobeNewswire
Nov-30-20 09:15AM	Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem GlobeNewswire
Nov-16-20 06:45AM	Iterum Therapeutics Reports Third Quarter 2020 Financial Results GlobeNewswire
Oct-23-20 12:02AM	Iterum Therapeutics Announces Pricing of $17.5 Million Upsized Public Offering GlobeNewswire -44.71%
Oct-19-20 07:10PM	UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 GlobeNewswire -5.03%
06:00PM	Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 GlobeNewswire
Oct-01-20 05:15PM	Is Iterum (ITRM) Stock Still Worth Buying After Its 85% Rally? Analyst Weighs In TipRanks +14.29%
Sep-30-20 07:45AM	The Daily Biotech Pulse: Eton Snags Second FDA Nod For Month, Vaccine Updates from Moderna, CureVac Benzinga +63.35%
07:00AM	Iterum Therapeutics Announces Positive Pre-NDA Meeting with FDA for Sulopenem for Treatment of Uncomplicated Urinary Tract Infections GlobeNewswire
Sep-08-20 04:30PM	Iterum Therapeutics to Present at the 22nd Annual H.C. Wainwright Global Investment Conference GlobeNewswire
Sep-02-20 07:00AM	Iterum Therapeutics Announces Revised Results of Rights Offering GlobeNewswire -7.00%
Aug-31-20 08:00PM	Iterum Therapeutics Announces Expiration and Preliminary Results of Rights Offering GlobeNewswire
Aug-11-20 08:00AM	Iterum Therapeutics Commences Rights Offering GlobeNewswire
Aug-06-20 06:45AM	Iterum Therapeutics Reports Second Quarter 2020 Financial Results GlobeNewswire
Jul-13-20 04:05PM	Iterum Therapeutics Informs Shareholders of Record Date for Planned Rights Offering GlobeNewswire
Jun-30-20 09:12AM	Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules GlobeNewswire -16.20%
Jun-29-20 07:30AM	Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections GlobeNewswire -7.19%
Jun-15-20 04:30PM	Iterum Therapeutics plc Announces Result of Proposal 8 at Annual General Meeting GlobeNewswire
Jun-03-20 03:45PM	Whats Next for Iterum (ITRM) After Sulopenem Fails Phase 3 Trial? Top Analyst Weighs In TipRanks -8.02%
09:50AM	Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules GlobeNewswire
Jun-02-20 09:42AM	Company News for June 2, 2020 Zacks
Jun-01-20 08:30AM	Iterum Therapeutics Announces Topline Results for a Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection GlobeNewswire -59.62%
May-14-20 09:31AM	3 Biotech Stocks Under $4 That Could Surge Over 50% TipRanks
06:45AM	Iterum Therapeutics Reports First Quarter 2020 Financial Results GlobeNewswire
Apr-09-20 04:05PM	Iterum Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-31-20 07:00AM	Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI) GlobeNewswire
Mar-12-20 06:45AM	Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire -9.85%
Feb-19-20 07:30AM	Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire +10.96%
Jan-17-20 06:15AM	Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors GlobeNewswire -26.01%
Jan-03-20 03:15PM	Riding December's Momentum Into 2020 Benzinga
Dec-26-19 05:00PM	Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infection GlobeNewswire
Dec-12-19 09:42AM	Iterum Down as Sulopenem Antibiotic Fails in Phase III Study Zacks -7.05%
Dec-11-19 07:21AM	The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint Benzinga -35.67%
Dec-10-19 04:10PM	Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections GlobeNewswire +21.86%
Nov-30-19 10:18AM	Is Iterum Therapeutics plc (ITRM) Going To Burn These Hedge Funds ? Insider Monkey
Nov-18-19 07:30AM	Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection GlobeNewswire +5.97%
Nov-12-19 07:05PM	Iterum Therapeutics PLC (ITRM) Reports Q3 Loss, Lags Revenue Estimates Zacks +5.65%
04:30PM	Iterum Therapeutics Reports Third Quarter 2019 Financial Results and Highlights GlobeNewswire
Nov-08-19 01:01PM	What Kind Of Shareholders Own Iterum Therapeutics plc (NASDAQ:ITRM)? Simply Wall St. +12.11%
Nov-06-19 10:30AM	Earnings Preview: Iterum Therapeutics PLC (ITRM) Q3 Earnings Expected to Decline Zacks -6.76%
Oct-01-19 10:07AM	Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 PR Newswire
Sep-27-19 04:30PM	Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-09-19 03:24PM	If You Had Bought Iterum Therapeutics (NASDAQ:ITRM) Stock A Year Ago, You'd Be Sitting On A 17% Loss, Today Simply Wall St. -8.91%
Aug-14-19 08:15AM	Iterum Therapeutics PLC (ITRM) Reports Q2 Loss, Misses Revenue Estimates Zacks -11.04%
07:00AM	Iterum Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-06-19 10:30AM	Iterum Therapeutics PLC (ITRM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Aug-01-19 07:30AM	Iterum Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference GlobeNewswire
Jul-10-19 12:13PM	Who Has Been Buying Iterum Therapeutics plc (NASDAQ:ITRM) Shares? Simply Wall St.
Jul-01-19 09:13AM	X-Biotix Therapeutics Joins Antimicrobials Working Group PR Newswire -7.70%
Jun-21-19 07:30AM	Iterum Therapeutics to Present Data on Uncomplicated Urinary Tract Infections at ASM Microbe 2019 GlobeNewswire
Jun-20-19 11:13AM	Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019 PR Newswire
Jun-07-19 09:27AM	Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections PR Newswire -9.54%
May-14-19 07:00AM	Iterum Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-12-19 10:08AM	Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-11-19 07:30AM	Iterum Therapeutics Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Activity of its Novel Antibiotic Sulopenem at ECCMID 2019 GlobeNewswire
Mar-28-19 09:00AM	Iterum Therapeutics PLC (ITRM) Moves to Buy: Rationale Behind the Upgrade Zacks
08:27AM	Will Iterum Therapeutics Continue to Surge Higher? Zacks
Mar-25-19 07:00AM	Iterum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire +10.18%
Mar-19-19 07:00AM	Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation GlobeNewswire +23.21%
Feb-21-19 10:15AM	What Kind Of Shareholders Own Iterum Therapeutics plc (NASDAQ:ITRM)? Simply Wall St.
Feb-19-19 07:30AM	Iterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference GlobeNewswire
Jan-17-19 10:00AM	Antimicrobials Working Group Announces Updates to Leadership Team PR Newswire
Dec-20-18 12:36PM	Are Insiders Buying Iterum Therapeutics plc (NASDAQ:ITRM) Stock? Simply Wall St. -8.71%
Nov-14-18 07:15AM	Iterum Reports Third Quarter 2018 Financial Results and Recent Highlights GlobeNewswire -10.46%
Nov-05-18 04:05PM	Iterum Therapeutics plc to Participate in Investor Conferences in November and December GlobeNewswire
Oct-05-18 08:00AM	Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018 GlobeNewswire
Sep-25-18 04:05PM	Iterum to Present at Cantor Fitzgerald Global Healthcare Conference GlobeNewswire -5.66%
Sep-20-18 08:00AM	Iterum Therapeutics to Present Clinical Data on Antibiotic Sulopenem at IDWeek 2018 GlobeNewswire -16.83%
Sep-18-18 08:00AM	Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections GlobeNewswire
Aug-14-18 07:30AM	Iterum Reports Second Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Aug-09-18 04:05PM	Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections GlobeNewswire
Jun-06-18 10:08AM	Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 PR Newswire
08:00AM	Iterum Therapeutics to Present Data on Prevalence of Resistant Infections and In Vitro Activity of its Novel Antibiotic Sulopenem PR Newswire
May-25-18 12:51AM	[$$] Drugmaker Iterum Therapeutics Bags $80 Million in IPO The Wall Street Journal
May-24-18 08:15PM	Iterum Therapeutics Announces Pricing of Initial Public Offering PR Newswire

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DENNER ALEXANDER J	10% Owner	Feb 12	Sale	2.27	10,619,949	24,107,284	0	Feb 12 08:22 PM
DENNER ALEXANDER J	10% Owner	Feb 11	Sale	2.59	10,000,000	25,900,000	10,619,949	Feb 12 08:22 PM
Fishman Corey N.	President & CEO	Jan 26	Sale	1.73	85,445	147,820	322,008	Jan 27 07:35 PM
Dunne Michael W.	Director	Jan 26	Sale	1.73	33,143	57,337	256,355	Jan 27 07:32 PM
Matthews Judith M.	Chief Financial Officer	Jan 26	Sale	1.73	33,868	58,592	28,632	Jan 27 07:32 PM
Matthews Judith M.	Chief Financial Officer	Sep 30	Sale	1.64	56,130	92,053	0	Oct 02 09:00 PM
Sofinnova Venture Partners IX,	10% Owner	Jun 02	Sale	1.61	400,000	642,960	1,226,514	Jun 03 08:20 PM
Sofinnova Venture Partners IX,	10% Owner	Jun 01	Sale	1.69	100,000	169,120	1,626,514	Jun 03 08:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience